Adjuvant nivolumab improves disease-free survival in patients with muscle invasive bladder cancer

Treatment with the PD1 inhibitor nivolumab with or without cisplatin-based chemotherapy after radical surgery significantly improve disease-free survival in patients with muscle-invasive urothelial cancer, regardless of PD-L1 status.